Pharmetheus at ACoP, Washington DC, US

Pharmetheus' presence at ACoP14 in November includes several exciting activities; workshops, posters, an oral presentation, and a booth where you can meet and discuss with our experienced consultants. Pre and post ACoP we will offer two workshops - secure your spot today!

Speed consulting – meet us at ACoP!

We will be present from 6th-8th of November, 2023 at ACoP. Please note that available time slots are limited. Sign up as soon as possible to give us a chance to help you tackle your challenges! Confidential disclosure agreement (CDA) will be arranged ahead of the meeting for those that require it. Just make sure to indicate this as you sign up…

Speed advising for students – meet us at ACoP!

Pharmetheus’ consultant experts offer to help you solve problems related to pharmacometrics and PBPK-QSP technical aspects, helping on modelling and simulation issues, in connection with the following software: R, NONMEM, PK-Sim and MoBi. A Confidential disclosure agreement (CDA) can be arranged ahead of the meeting for those that require it. Just make sure to indicate this as you sign up…

Sunday 5 November

IS_16x10_Pharmetheus_07_TrainingWorkshop_C

Workshop: An introduction to probabilistic decisions support in drug development

Do you want to improve decision making in drug development? This workshop aims to introduce how Model Informed Drug Development (MIDD) principles can be applied to facilitate probability-based decision making in drug development. Join this 1 day workshop led by Pharmetheus’ experts and held on Sunday 5th of November 2023 in connection to ACoP14, Washington DC, US.

Read more about Workshop: An introduction to probabilistic decisions support in drug development

Monday 6 November

Symposium session chaired by Anna Mc Laughlin 2.30 – 4.00 PM

Opportunities for MIDD for cell therapies

Model-based optimization for (CAR-T) Cell Therapies – The current state of affairs and a way forward. Anna Mc Laughlin, Dr. rer.nat, Consultant. PharmetheusCassian Yee, Professor, University of Texas MD Anderson Cancer Center Cellular therapy, especially chimeric antigen receptor (CAR)-T cell therapy, has revolutionized the treatment of relapsed/refractory hematological malignancies. Several modeling and…

Read more about Opportunities for MIDD for cell therapies

Poster M-017 presented by Anna Mc Laughlin 7-9am, 1-2.30 pm, 5-6pm

Exploring the relationship between BI 456906 exposure and change in fasting plasma glucose, fasting serum insulin, and glycated hemoglobin (HbA1c) using population PKPD modeling

This poster dissects the direct and indirect effects of survodutide, a dual glucagon and GLP1 receptor agonist, on metabolic markers in patients with type 2 diabetes mellitus.

Read more about Exploring the relationship between BI 456906 exposure and change in fasting plasma glucose, fasting serum insulin, and glycated hemoglobin (HbA1c) using population PKPD modeling

Poster M-122L presented by Niclas Jonsson 7-9am, 1-2.30 pm, 5-6pm

Checklists and best practices to support the informed use of Forest plots to illustrate the impact of covariates in pharmacometric models

The poster discusses the challenges when using forest plots for communicating covariate effects in pharmacometric analyses. It suggests best practices and provides checklists for both the creator and reviewer of forest plots.

Read more about Checklists and best practices to support the informed use of Forest plots to illustrate the impact of covariates in pharmacometric models

Wednesday 8 November

Poster W-071 presented by Tobias Kanacher 7-9am, 12-1.30pm

Development of a Physiologically-Based Pharmacokinetic Model for Coproporphyrin I (CP-I) Using the Open Systems Pharmacology Software Suite (PK-Sim and MoBi) for assessment of OATP1B-based DDIs

This poster describes a Coproporphyrin (CP-I) PBPK-model, which can be used in the freely accessible Open Systems Pharmacology Suite (PK-Sim and MoBi) to assess potential drug-drug interaction of new therapeutic drugs via OATP1B.

Read more about Development of a Physiologically-Based Pharmacokinetic Model for Coproporphyrin I (CP-I) Using the Open Systems Pharmacology Software Suite (PK-Sim and MoBi) for assessment of OATP1B-based DDIs

Thursday 9-10 November

Workshop: ‘PBPK-PD/QSP modeling with the OSPSuite (PK-Sim®, MoBi®)’

Interested in combining PBPK and PD/QSP models and looking for efficient means to accomplish this? Join this 1,5 day workshop led by Pharmetheus’ experts and held on Thursday-Friday 9th-10th of November 2023 in connection to ACoP14, Washington DC, US.

Read more about Workshop: ‘PBPK-PD/QSP modeling with the OSPSuite (PK-Sim®, MoBi®)’